US Global Jets ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? US Global Jets ETF trades at $27.48 (market cap $878.48M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 28.8× US Global Jets ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while US Global Jets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 26 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| JETS | RPRX | |
|---|---|---|
Market Cap | $878.48M | $25.27B |
Volume | 4,402,990 | 3,671,183 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $63.96 |
52-Week Low | $23.64 | $35.44 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
JETS trades at $27.67, down 1.53% with a bearish technical outlook. The ETF faces headwinds from rising fuel costs and geopolitical tensions impacting airline profitability. Recent news highlights underperformance versus aerospace/defense ETFs, with competitors like ARKX and ITA showing stronger returns. Technical indicators show oversold conditions on short-term RSI but overall bearish momentum from moving averages.
The outlook remains challenged by fuel price volatility and competitive pressure from alternative aviation ETFs. Near-term support at $27 could provide a technical floor, but sustained recovery requires easing of fuel cost pressures and improved airline earnings visibility. The ETF's concentration in pure airline operators increases sensitivity to industry-specific risks.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →